Product Description
a predominant ETAreceptor antagonist (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831858/)
Mechanisms of Action: ETa Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Speedel Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diabetic Nephropathy|Kidney Failure, Chronic
Phase 2: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
2008-000786-32 | P2 |
Completed |
Kidney Diseases |
2009-09-11 |
2022-03-12 |
Treatments |
|
ASCEND | P3 |
Terminated |
Diabetic Nephropathy |
2006-12-18 |
2022-03-12 |
Treatments |
|
SPP301CRD15 | P3 |
Terminated |
Diabetic Nephropathy|Kidney Failure, Chronic |
None |
2019-03-21 |
Treatments |